Companies › ArthroBiologix
1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 4, 1 Phase 3; Immunology, Oncology, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Platelet-rich plasma (PRP) Autologous platelet-rich plasma derived from patient blood | – | Phase 4 | Osteoarthritis, Knee; Olfactory Dysfunction; Breast Cancer; Trochanteric Syndrome | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04111718 | Platelet-rich plasma (PRP) | Phase 4 | Osteoarthritis, Knee | Immunology | Dec 2025 |
| NCT05812924 | Platelet-rich plasma (PRP) | Phase 2 | Breast Cancer | Oncology | Sep 2026 |
| NCT07151703 | Platelet-rich plasma (PRP) | Phase 3 | Olfactory Dysfunction | Other | Dec 2027 |
| NCT07396246 | Platelet-rich plasma (PRP) | Phase 2 | Trochanteric Syndrome | Other | Dec 2027 |
No annotated target.
–
ALK-Abelló CellTherX Kolon TissueGene Gradalis Doron Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.